Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMEB-SASS for Recessive Dystrophic Epidermolysis Bullosa
NCT07193134Phase 2Recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 2 trial of GMEB-SASS in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by CHU de Québec-Université Laval. Started Jan 2026; status: recruiting.
02
Drugs
GMEB-SASS
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT07193134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193134.